Healthcare provider profile · identity verified

John Wallace Galbreath, MD

Internal Medicine · WINSTON SALEM, NC · NPI 1891799433

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	736	217
Atorvastatin Calcium	Atorvastatin Calcium	587	163
Amlodipine Besylate	Amlodipine Besylate	410	114
Lisinopril	Lisinopril	374	104
Levothyroxine Sodium	Levothyroxine Sodium	294	77
Metoprolol Succinate	Metoprolol Succinate	246	73
Losartan Potassium	Losartan Potassium	233	69
Gabapentin	Gabapentin	231	69
Valsartan	Valsartan	207	62
Simvastatin	Simvastatin	203	56
Omeprazole	Omeprazole	192	55
Tamsulosin Hcl	Tamsulosin Hcl	159	46
Metformin Hcl	Metformin Hcl	152	44
Eliquis	Apixaban	146	37
Alprazolam	Alprazolam	141	32
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	140	38
Jardiance	Empagliflozin	129	27
Allopurinol	Allopurinol	127	38
Furosemide	Furosemide	126	43
Metformin Hcl Er	Metformin Hcl	121	37
Pravastatin Sodium	Pravastatin Sodium	115	32
Pantoprazole Sodium	Pantoprazole Sodium	114	35
Escitalopram Oxalate	Escitalopram Oxalate	112	31
Sertraline Hcl	Sertraline Hcl	98	28
Hydrochlorothiazide	Hydrochlorothiazide	96	30
Zolpidem Tartrate	Zolpidem Tartrate	87	29
Carvedilol	Carvedilol	81	27
Glipizide Er	Glipizide	80	24
Fluticasone Propionate	Fluticasone Propionate	76	23
Finasteride	Finasteride	72	18
Metoprolol Tartrate	Metoprolol Tartrate	69	23
Mirtazapine	Mirtazapine	67	23
Potassium Chloride	Potassium Chloride	66	17
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	63	16
Trazodone Hcl	Trazodone Hcl	62	19
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	60	18
Albuterol Sulfate Hfa	Albuterol Sulfate	55	20
Clopidogrel	Clopidogrel Bisulfate	55	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	15
Lorazepam	Lorazepam	52	11
Warfarin Sodium	Warfarin Sodium	52	16
Xarelto	Rivaroxaban	47	suppressed
Glimepiride	Glimepiride	46	11
Chlorthalidone	Chlorthalidone	45	11
Tramadol Hcl	Tramadol Hcl	44	17
Citalopram Hbr	Citalopram Hydrobromide	43	12
Ezetimibe	Ezetimibe	41	12
Famotidine	Famotidine	40	12
Tizanidine Hcl	Tizanidine Hcl	39	14
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	37	suppressed
Celecoxib	Celecoxib	37	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	36	16
Hydralazine Hcl	Hydralazine Hcl	35	suppressed
Spironolactone	Spironolactone	35	12
Atenolol	Atenolol	34	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	34	suppressed
Ipratropium Bromide	Ipratropium Bromide	34	suppressed
Clonazepam	Clonazepam	33	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	32	suppressed
Bupropion Xl	Bupropion Hcl	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Buspirone Hcl	Buspirone Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Glipizide	Glipizide	22	suppressed
Labetalol Hcl	Labetalol Hcl	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Myrbetriq	Mirabegron	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	suppressed
Lovastatin	Lovastatin	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	20	19
Prednisone	Prednisone	20	19
Repaglinide	Repaglinide	20	suppressed
Cefuroxime	Cefuroxime Axetil	19	16
Pregabalin	Pregabalin	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Midodrine Hcl	Midodrine Hcl	18	suppressed
Topiramate	Topiramate	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	12
Felodipine Er	Felodipine	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	15
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Colchicine	Colchicine	14	suppressed
Torsemide	Torsemide	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Klor-Con M20	Potassium Chloride	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Chlorzoxazone	Chlorzoxazone	12	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Diazepam	Diazepam	12	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error